Tag Archive for: NEPC
Phase 1 Trial of 225Ac-ETN029 for Neuroendocrine Prostate Cancer
/in Clinical Trial, Metastatic, Phase 1/by MaxPhase 1/2 Trial: MT-4561 Targeting BRD4 in Metastatic Prostate Cancer and Neuroendocrine Prostate Cancer
/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxNEPC
Phase 2 Trial: ZG006 a New Immunotherapy for Neuroendocrine Prostate Cancer
/in Clinical Trial, Metastatic, Phase 2/by MaxPreclinical: Targeting NSD2, a Promising Strategy Against Treatment-Induced Neuroendocrine Prostate Cancer
/in Preclinical Research/by MaxNew Hope for Neuroendocrine Prostate Cancer: Targeting Mitochondrial HSP60
/in Preclinical Research/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 225Ac abiraterone abiraterone acetate ADC ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T CD3 clinical trial crispr darolutamide docetaxel drug repurposing enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP1 PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data STEAP1 T-cell therapy
Latest Posts
- Sonodynamic Nanotherapy: A New Strategy to Destroy Bone Metastases July 10, 2026
- Fully human antibody against TβRI halts tumor growth and metastasis in preclinical prostate cancer models July 9, 2026
- UPDATE: AO-252 Demonstrates 80% Clinical Benefit Rate as Development Shifts to Expansion Phase July 8, 2026
- Phase 3 Trial: Metformin in Men Receiving ADT for Prostate Cancer July 8, 2026